1 / 14

C ollaborative HI V P aediatric S tudy ( CHIPS )

Older and wiser: continued improvements in clinical outcome and highly active antiretroviral therapy (HAART) response in HIV-infected children in the UK and Ireland, 1996-2005. C ollaborative HI V P aediatric S tudy ( CHIPS )

arkadiy-popov
Download Presentation

C ollaborative HI V P aediatric S tudy ( CHIPS )

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Older and wiser: continued improvements in clinical outcome and highly active antiretroviral therapy (HAART) response in HIV-infected children in the UK and Ireland, 1996-2005 Collaborative HIV Paediatric Study (CHIPS) A Judd, T Duong, KJ Lee, AS Walker, PA Tookey, M Sharland,A Riordan, H Lyall, J Masters, E Menson, G Tudor-Williams,K Butler, S Donaghy, V Novelli, C Peckham, DM Gibb

  2. Introduction to CHIPS & NSHPC • Surveillance of obstetric and paediatric HIV in the UK and Ireland is carried out through the National Study of HIV in Pregnancy and Childhood (NSHPC) • CHIPS is a multicentre cohort study of HIV infected children under care in 39 hospitals in the UK & Ireland since 1996 • 90% children currently in NSHPC are also in CHIPS • detailed annual follow up questionnaires • For those not in CHIPS, NSHPC collects limited annual follow up data

  3. Aim • Describe changes over time in demographics, morbidity and mortality, and exposure and response to HAART • HIV infected children in the UK & Ireland • 1996 - 2005

  4. Methods • HAART exposure and response data are for CHIPS children only (n=1065). All other analyses include all diagnosed children (n=1439) • Logistic regression to explore 12 month viral load and CD4% responses to HAART in ART naïve children

  5. Regional distribution of children 5% Scotland <1% N. Ireland 23% Rest of England 5% Ireland 1% Wales 66% London

  6. Sociodemographics Sex:How child was identified: Female 50% Prospectively 13% Before AIDS 68% Ethnicity: AIDS diagnosis 19% Black African 72% White 13% Source of infection: Other 16% Vertical 94% Blood transfusion 3% % born abroad: Other 3% Early 1990s ~30% 2000+ ~65%

  7. Age group & sample size by year N: 386 425 505 561 647 745 837 954 1006 802* * 2005 = provisional data, subject to reporting delay

  8. HAART exposure and switching • 595 children started a HAART regimen since 1997 and were ART naïve before HAART • median age = 5 years (IQR 2-9) • Median time to switching to 2nd line =7.2 yrs • [switching = 2 drugs substituted because of failure (CD4/ VL/ clinical/ resistance), or all drugs changed] • At last follow up: • 33% of 10-14 year olds and 41% aged 15 were triple class exposed • 9% of 10-14 year olds and 14% aged 15 were off all ART, after previously receiving HAART

  9. VL decrease <400 c/ml at 12 months Variable % Odds ratio(95%CI) Year started HAART 1997/9 (baseline) 51% 1.00 2000/2 70% 2.27 (1.30-3.96) 2003/5 76% 2.99 (1.60-5.59) • No effect of age, or viral load at HAART All ORs are adjusted for: age, CD4% and HIV-1 RNA at HAART initiation; sex; CDC B/C events prior to HAART; number of drugs in the initial HAART regimen; year started HAART; and timing of response measurements

  10. CD4% increase >10% at 12 months Variable Odds ratio(95%CI) Age at HAART (per year) 0.85 (0.78-0.92) CD4% at HAART (per 5%) 0.55 (0.47-0.64) Sex Male (baseline) 1.00 Female 1.68 (1.01-2.81) • No effect of calendar year All ORs are adjusted for: age, CD4% and HIV-1 RNA at HAART initiation; sex; CDC B/C events prior to HAART; number of drugs in the initial HAART regimen; year started HAART; and timing of response measurements

  11. Rates of progression to AIDS/ death

  12. Deaths in 2003/5 • 18 children died between 2003/5. Of these: • 7 presented with AIDS/ died within one month • Of the remaining 11: • only 3 were on HAART for 6+ months prior to death • primary cause of death was opportunistic infections (2), HIV encephalopathy (1), sepsis (1), lung disease (1), gastrointestinal bleeding (1), chickenpox/ cardiovascular (1), neurocysticercosis • cause of 3 deaths unknown: • 1 was diagnosed at 4 months & died 6 weeks later; 2 were diagnosed at birth but subsequently returned to Africa and died there

  13. Conclusions • Mortality and rates of progression to AIDS have continued to decline since HAART • Viral load suppression 12 months after HAART initiation improved with time • Low rates of switching to 2nd line therapy • Increased triple class exposure complicates clinical management • Provision of transitional services and continued monitoring essential as the cohort ages into adolescence and adulthood

  14. Acknowledgements • We thank: • staff and families from the hospitals collaborating in CHIPS, and Gill Wait, CHIPS Data Manager • all paediatricians and other health professionals reporting to the NSHPC, and the British Paediatric Surveillance Unit of the Royal College of Paediatrics and Child Health • UK Department of Health, HPA, Bristol-Myers Squibb, Boehringer-Ingelheim, GlaxoSmithKline, Roche, Abbott and Gilead for financial support • www.chipscohort.ac.uk

More Related